arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Enveric Biosciences, Inc.

ENVB
$1.41 ▼ -0.03 (-2.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enveric Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -29.6% ↘
FCF / Share $-0.61 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.48M
↓ -7.3% —
Net Income Profit after all expenses
$-1.63M
↑ +25.2% —
Operating Margin Operating profit as % of sales
-13.2%
↑ +8.2% —
FCF / Share Free cash flow per share
$-0.61
↑ +59.0% —
Long-Term Debt Long-term obligations
$1.70K
↓ -99.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Financial Health ↓
0
Cash Quality ↑
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 59 quarters